Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
Sponsor: James J. Peters Veterans Affairs Medical Center
Summary
The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2021-11-01
Completion Date
2027-11-01
Last Updated
2025-09-17
Healthy Volunteers
No
Conditions
Interventions
Romosozumab
Romosozumab (Amgen Inc., Thousand Oaks, CA) 210mg SQ administered each month
Denosumab
Denosumab (Amgen Inc., Thousand Oaks, CA) 60 mg SQ administered every six months
Locations (2)
Kessler Institute for Rehabilitation
West Orange, New Jersey, United States
James J. Peters VA Medical Center
The Bronx, New York, United States